Belgium And Lund
LEUVEN, Belgium and LUND, Sweden, December 16, 2011 -
ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 (factor VIII inhibitor) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery.
LEUVEN, Belgium and LUND, Sweden, May 16, 2011 - ThromboGenics NV (Euronext Brussels: THR) and co-development partner
BioInvent International AB (OMXS: BINV) announce today that their partner
Roche (SIX: RO, ROG; OTCQX: RHHBY) has dosed the first patient in a Phase
Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
LEUVEN, Belgium and LUND, Sweden, April 27, 2011 - ThromboGenics NV (Euronext Brussels: THR) and co-development
partner BioInvent International (OMXS: BINV) announce today that the first
patient has been dosed in a Phase IIb trial with their novel long-acting
anticoagulant TB-402 (Anti-Factor VIII) for the prophylaxis of venous
thromboembolism (VTE) after total hip surgery.
LEUVEN, Belgium and LUND, Sweden, February 11, 2011 - ThromboGenics NV (Euronext Brussels: THR) and co-development
partner BioInvent International (OMXS: BINV) announce today that the positive
TB-402 (Anti-Factor VIII) Phase II trial results, evaluating the product's
efficacy and safety for the prevention of venous thromboembolism (VTE)
afterorthopaedic surgery, have been published in the Journal of Thrombosis
and Haemostasis.
LEUVEN, Belgium and LUND, Sweden, May 17, 2010 - ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) announce today that their partner Roche (SIX:
RO, ROG; OTCQX: RHHBY) will begin an imaging study with the novel anti-cancer
antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory,
colorectal and ovarian cancers.
